Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 14, 2015; 21(38): 10874-10882
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10874
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10874
Figure 3 Virologic responses according to the presence of favorable factors.
A: Cumulative virologic response rates in patients with low baseline serum hepatitis B virus (HBV) DNA levels and in patients with high baseline serum HBV DNA levels (P < 0.001); B: Cumulative virologic response rates in patients with and without initial virologic response-3 (IVR-3) (P < 0.001).
- Citation: Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882
- URL: https://www.wjgnet.com/1007-9327/full/v21/i38/10874.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i38.10874